The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose escalation of five-fraction SABR for prostate cancer: Biochemical outcome and toxicity comparison of two prospective trials.
 
Hima Bindu Musunuru
No Relationships to Disclose
 
Harvey Charles Quon
No Relationships to Disclose
 
Liying Zhang
No Relationships to Disclose
 
Patrick Cheung
Research Funding - Abbvie (Inst); Pfizer (Inst); Sanofi (Inst)
 
Colin I Tang
No Relationships to Disclose
 
Geordi Pang
No Relationships to Disclose
 
Alexandre Mamedov
No Relationships to Disclose
 
Laura D'Alimonte
No Relationships to Disclose
 
Andrea Deabreu
No Relationships to Disclose
 
D. Andrew Loblaw
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (I); Elekta; GlaxoSmithKline (I); Janssen Oncology; Merck (I); Novartis (I); Paladin; Roche (I); Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb (I); GlaxoSmithKline (I); Janssen Oncology; Merck (I); Novartis (I); Roche (I); Sanofi
Research Funding - Paladin (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Janssen Oncology; Paladin